DiaMedica Therapeutics (NASDAQ:DMAC) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. “

Separately, Roth Capital dropped their target price on DiaMedica Therapeutics from $32.00 to $24.00 and set a buy rating on the stock in a research note on Monday, September 27th.

Shares of DMAC stock opened at $3.38 on Wednesday. DiaMedica Therapeutics has a 1-year low of $3.00 and a 1-year high of $10.88. The stock’s fifty day moving average price is $3.76 and its 200 day moving average price is $3.87.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, November 10th. The company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.05. During the same period in the previous year, the company earned ($0.19) EPS. On average, equities research analysts forecast that DiaMedica Therapeutics will post -0.73 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of DMAC. Bank of Montreal Can grew its stake in DiaMedica Therapeutics by 36.7% during the 2nd quarter. Bank of Montreal Can now owns 142,846 shares of the company’s stock valued at $694,000 after purchasing an additional 38,322 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at about $37,000. Dimensional Fund Advisors LP acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at about $63,000. Trexquant Investment LP acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at about $76,000. Finally, Geode Capital Management LLC lifted its holdings in shares of DiaMedica Therapeutics by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 133,569 shares of the company’s stock valued at $594,000 after buying an additional 5,101 shares during the period. Institutional investors and hedge funds own 49.45% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Further Reading: What are the advantages to having securities held in street name?

Get a free copy of the Zacks research report on DiaMedica Therapeutics (DMAC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.